Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab-mediated eosinophil depletion and immune response study in severe asthma
NL-OMON45798Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of mepolizumab in asthma and severe asthma, sponsored by Amsterdam University Medical Center. Primary endpoints: Primary endpoint: genotyping of white blood cells, Primary endpoint: humoral parameters and 5 more. Planned start Oct 2017; status: withdrawn.
02
Drugs
mepolizumab
03
Conditions
asthmasevere asthma
Beyond the preview
Go deeper on NL-OMON45798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45798.